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Background: N-stage is related to distant metastasis of nasopharyngeal carcinoma (NPC) patients. We performed
this study to compare the efficacy of different chemotherapy sequences in advanced N-stage (N2 and N3) NPC
patients treated with intensity modulated radiotherapy (IMRT).
Methods: From 2001 to 2008, 198 advanced N-stage NPC patients were retrospectively analyzed. Thirty-three
patients received IMRT alone. Concurrent chemoradiotherapy (CCRT) was delivered to 72 patients, neoadjuvant
chemotherapy (NACT) + CCRT to 82 patients and CCRT + adjuvant chemotherapy (AC) to 11 patients.
Results: The 5-year overall survival rate, recurrence-free survival rate, distant metastasis-free survival rate and
progress-free survival rate were 47.7% and 73.1%(p<0.001), 74.5% and 91.3% (p = 0.004), 49.2% and 68.5% (p = 0.018),
37.5% and 63.8% (p<0.001) in IMRT alone and chemoradiotherapy group. Subgroup analyses indicated that there were
no significant differences among the survival curves of CCRT, NACT + CCRT and CCRT + AC groups. The survival benefit
mainly came from CCRT. However, there was only an improvement attendency in distant metastasis-free survival rate
of CCRT group (p = 0.107) when compared with RT alone group, and NACT + CCRT could significantly improve distant
metastasis-free survival (p = 0.017).
Conclusions: For advanced N-stage NPC patients, NACT + CCRT might be a reasonable treatment strategy.
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Although rare among the Caucasian population, naso-
pharyngeal carcinoma (NPC) is rather common among
Asians, especially the Southern Chinese [1]. Intensity-
modulated radiotherapy (IMRT) is a major breakthrough
in the treatment of NPC. It enables the delivery of higher
radiation dose to the lesion while sparing the organs/
tissues at risk, thus enhancing the therapeutic ratio,
and has been accepted as a more advantageous technique* Correspondence: lutx@sysucc.org.cn
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reproduction in any medium, provided the oras compared with two-dimensional conventional radiother-
apy (2D-CRT). Previous studies have confirmed that IMRT
changed the failure pattern of NPC from local recurrence
and distant metastasis to predominantly distant metastasis
in patients treated with 2D-CRT [2,3].
It is well known that N-stage is related to distant metas-
tasis of NPC patients. Wong et al. [2] reviewed 175 NPC
patients treated with IMRT and found that the 3-year dis-
tant failure-free survival rate was 95.4%, 100%, 76.6%, and
67.3% for stage N0, N1, N2, and N3 patients, respectively.
The Cox proportional hazards regression analysis showed
that advanced N-stage was a significant predictor of dis-
tant metastasis (p = 0.029). Therefore, it is necessary to ex-
plore more effective combined chemoradiation strategies. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Baseline characteristics of the 198 patients
Characteristic IMRT alone CCRT NACT + CCRT CCRT + AC P
Age(years) 0.099
Median 42 44 38 33
Range 18-78 13-70 16-63 31-57
Gender 0.598
Male 24 56 66 10
Female 9 16 16 1
T stage 0.097
T1-2 17 28 23 3
T3-4 16 44 59 8
N stage 0.087
N2 32 62 67 11
N3 1 10 15 0
Histology 0.740
WHO I 0 0 1 0
WHO II 5 7 9 0
WHO III 28 65 72 11
Abbreviation: IMRT alone: intensity-modulated radiotherapy alone; CCRT: concurrent
chemoradiotherapy; NACT+ CCRT: neoadjuvant chemotherapy and concurrent
chemoradiotherapy; CCRT + AC: concurrent chemoradiotherapy and
adjuvant chemotherapy.
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with NPC.
According to the results of previously reported phase
III clinical trial and meta-analysis [4-6], concurrent che-
moradiotherapy had the most definite survival benefit
for locoregionally advanced NPC and had became a
standard treatment regimen. However, in these trials and
meta-analysis, 2D-CRT technique was adopted for radio-
therapy. To our knowledge,there was no phase β clinical
trials to identify the value of chemotherapy on locore-
gionally advanced NPC treated with IMRT. Especially
for advanced N-stage patients (whose key problem is
distant failure), it is unknown whether chemotherapy
could reduce distant metastasis rate and improve treat-
ment outcomes. Therefore, we retrospectively analyzed
the long term outcomes of advanced N-stage NPC pa-
tients treated with IMRT, and performed the analysis to
compare the efficacy of different chemotherapy sequences
in these patients.
Methods
Patients and patient workup
Between February 2001 and January 2008, 198 histologi-
cally proven, newly diagnosed, advanced N-stage NPC
patients had undergone full-course definitive IMRT at
the Cancer Center of Sun Yat-Sen University of the 198
patients, there were 156 males and 42 females, with a
sex ratio of 3.7:1, and the age range was 13 to 78 years
(the median age is 41 and there were 3 patients less than
18 years). The routine workup included a complete phys-
ical examination, hematologic and biochemistry profiles,
fiberoptic endoscope examination of the nasopharynx,
magnetic resonance imaging, or contrast-enhanced com-
puted tomography (CT) of the head and neck to accurately
evaluate the extent of the primary tumor and regional
lymph nodes. Chest radiography, bone scintigraphy, and
ultrasonography of the abdominal region were used to
exclude distant metastasis. All patients underwent disease
staging using the AJCC 2002 staging system. The baseline
clinical characteristics are listed in Table 1.
Target volume delineation and evaluation of IMRT planning
All patients were immobilized in the supine position
with a head, neck, and shoulder thermoplastic mask.
CT simulation was performed with a slice thickness of
3 mm extending from the vertex to 2 cm below the clav-
icle. Both plain CT and contrast-enhanced CT images were
obtained and transferred to inverse treatment-planning
system (CORVUS 3.0/3.2,Peacock plan) developed by
NOMOS Corporation. The primary tumor area and the
upper-neck area above the caudal edge of the cricoids
cartilage were treated by IMRT. Target volumes were de-
lineated according to our institutional treatment protocol
[7], in agreement with the International Commission onRadiation Units and Measurements Reports (ICRU)50 and
62. Planning target volumes (PTVs) for all gross tumor vol-
umes and clinical target volumes (CTVs) were generated
automatically after delineation of tumor targets according
to the immobilization and localization uncertainties.
Inverse planning was performed on the Corvus System
for all patients using Simultaneous Modulated Accelerated
Radiation Therapy boost RT [8]. The prescribed dose was
68Gy to the PTV of the GTVnx, 60Gy to the PTV of
CTV1, 54Gy to the PTV of CTV2, and 60-66Gy to the
PTV of the GTV for the positive cervical lymph nodes in
30 fractions. The prescribed dose to the lower neck and
the supraclavicular fossae by irradiation with conventional
RT technique was 50Gy/25 fraction for prophylactic intent
in whole neck group.
The dose-volume histograms of the treatment targets
and critical normal structures were evaluated. For GTV
and CTV, the target volumes receiving ≥ 95% of the pre-
scribed dose was used to reflect the target coverage. For
the critical organs with functional subunits organized in
series, the dose to 5% of the volume couldn’t exceed their
tolerance doses. For the critical organs with functional sub-
units organized in parallel, the dose constraints to 33% of
the volume were less than their tolerance doses.
Chemotherapy
During the study period, we followed our institutional
guidelines (Sun Yat-sen University Cancer Center IRB),
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therapy and/or concomitant chemotherapy for the pa-
tients. Deviation from the institutional guidelines were
because of organ dysfunction, suggesting intolerance to
the chemotherapy, and patient refusal.
Chemotherapy was administered to 165 patients. Con-
current chemotherapy (CCT) was delivered to 72 pa-
tients, neoadjuvant chemotherapy (NACT) + CCT to 82
patients and CCT + adjuvant chemotherapy (AC) to 11
patients. The regimens of NACT included TC (paclitaxel
135 mg/m2 IV on day 1 and carboplatin AUC = 6 IV on
day 1) and PF (cisplatin 80 mg/m2 IV on day 1 and 5-Fu
800 mg/m2/d continuously IV on day 1–5). There were
33 patients received TC regimen and 49 patients received
PF regimen. Regimens were repeated every 3 weeks for 2–
3 cycles. CCT included three regimens. Cisplatin (CDDP)
80 mg/m2 IV every 3 weeks was delivered to 92 patients,
CDDP 30-40 mg/m2 IV weekly was delivered to 47 pa-
tients, and PF regimen (the same as NACT) was delivered
to 26 patients. For patients who received adjuvant chemo-
therapy, PF regimen (the same as NACT) were repeated
every 3 weeks for 2–4 cycles.
Follow-up and statistical analysis
After RT completion, the patients were subsequently
followed up monthly for the first 3 months, every 3 months
through 3 years, every 6 months for the next 2 years, and
then annually. The median follow-up period was 56 months
(range, 3–120 months). The survival time was measure
from first day of RT completion to the date of the event
or last follow-up visit. The Statistical Package for Social
Sciences, version 16.0 (SPSS,Chicago, IL) was used for
statistical analysis. The Kaplan-Meier method was used
to calculate the overall survival (OS), recurrence-free
survival (RFS), distant metastasis-free survival (DMFS),
and progress-free survival (PFS) rates. The log-rank test
was used to compare the survival curves. All statistical




For all patients, the 5-year OS, RFS, DMFS, and PFS
rates were 69%, 89%, 65%, and 59%, respectively. OS,
RFS, DMFS and PFS rates were significantly higher in
patients treated with chemoradiotherapy than those treated
with IMRT alone (5-year OS rate: 47.7% vs. 73.7%, p<0.001;
RFS: 74.5% vs. 91.3%, p = 0.004; DMFS: 49.2% vs. 68.5%,
p = 0.018; PFS: 37.5% vs. 63.8%, p<0.001). Patients treated
with chemoradiotherapy were divided into three groups:
CCRT (Concurrent chemoradiotherapy) group, NACT+
CCRT group, and CCRT +AC group. The 5-year OS rates
of the three chemoradiotherapy groups were 70.3%, 76.1%,
and 79.5%, respectively. Compared with IMRT alone, theOS of these three groups were significantly higher. But
there were no statistically significant difference among
these three groups. The 5-year RFS rates of the three
chemoradiotherapy groups were 92.4%, 90.6%, and 90.9%,
respectively. Compared with IMRT alone, CCRT and
NACT + CCRT improved RFS significantly. The 5-year
DMFS rates of the three chemoradiotherapy groups were
64.3%, 71.1%, 79.5%, respectively. Compared with IMRT
alone, only NACT + CCRT could significantly improve
DMFS rate, while there was only a trend in CCRT and
CCRT +AC group. There was no statistical significance
among the difference of the three chemoradiotherapy
groups. The 5-year PFS rates of the three chemoradio-
therapy groups were 60.2%, 66.4%, and 70.1%, respect-
ively. Compared with IMRT alone, the PFS of these three
groups were significantly higher, but there was no sta-
tistically significant difference among the three groups
(Figures 1, 2, 3 and 4).
At their last follow-up visit, 79 patients had developed
treatment failure. Of the 79 patients, 6 had primary re-
currence, 3 had regional nodal recurrence, 4 had pri-
mary and regional nodal recurrence, and 66 had distant
metastasis, respectively.Among them, 3 had developed
primary recurrence and distant metastasis, and 4 had de-
veloped regional nodal recurrence and distant metasta-
sis. Thirty-five patients had developed distant metastasis
in a single organ: 15 cases in bone, 10 cases in liver, 9
cases in lung, and 1 case in mediastinal lymph node.
Twenty-four patients had developed multi-organ metas-
tasis. The 79 patients with treatment failure are listed in
Table 2.
Prognostic factors
Univariate analysis by log-rank test revealed that T stage
and treatment method were prognostic factors for OS
and DMFS. And treatment method was prognostic fac-
tor for RFS and PFS (Table 3).
All characteristics of survival were analyzed by COX
regression model. Adjusted by age, gender and histology,
multivariate analysis showed that T stage, N stage and
treatment method were independent prognostic predic-
tors of OS, DMFS and PFS. Only treatment method was
independent prognostic predictors of RFS (Table 4).
Toxicity
Treatment-related toxicity was scored according to the
Radiation Therapy Oncology Group radiation morbidity
scoring criteria. For the patients treated with IMRT alone,
the most frequently observed acute toxicity was mainly
grade 1 or 2 xerostomia and mucositis. The incidence of
acute grade 3 mucositis was 24.2%. Six patients (18.2%)
had grade 1 leukopenia and/or neutropenia. No grade 4
acute toxicities were observed. For the patients treated
with chemoradiotherapy, seventy-six patients (46.1%) had
Figure 1 Overall survival rates of 198 advanced N-stage patients treated with different methods (RT:CCRT χ2 = 8.942,P = 0.003; RT:
NACT + CCRT χ2 = 9.357, P = 0.002; RT:CCRT + AC χ2 = 4.413,P = 0.036; CCRT:NACT + CCRT χ2 = 0.031,P = 0.860; CCRT:CCRT + AC χ2 = 0.348,
P = 0.555; NACT + CCRT: CCRT + AC χ2 = 0.284,P = 0.594).
Figure 2 Recurrence-free survival rates of 198 advanced N-stage patients treated with different methods (RT:CCRT χ2= 6.673,P= 0.010; RT:
NACT +CCRT χ2= 5.461, P= 0.019; RT:CCRT +AC χ2= 1.621,P= 0.203; CCRT:NACT + CCRT χ2= 0.131,P= 0.717; CCRT:CCRT +AC χ2 = 0.062,
P= 0.804; NACT + CCRT: CCRT +AC χ2= 0.001,P= 0.977).
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Figure 3 Distant metastasis-free survival rates of 198 advanced N-stage patients treated with different methods (RT:CCRT χ2 = 2.600,
P = 0.107; RT:NACT + CCRT χ2 = 5.694, P = 0.017; RT:CCRT + AC χ2 = 3.174,P = 0.075; CCRT:NACT + CCRT χ2 = 0.427,P = 0.672; CCRT:CCRT +
AC χ2 = 0.991,P = 0.320; NACT + CCRT: CCRT + AC χ2 = 0.497,P = 0.481.
Figure 4 Progress-free survival rates of 198 advanced N-stage patients treated with different methods (RT:CCRT χ2 = 6.969,P= 0.008; RT:
NACT + CCRT χ2 = 10.969, P = 0.001; RT:CCRT +AC χ2 = 4.376,P = 0.036; CCRT:NACT + CCRT χ2 = 0.481,P = 0.488; CCRT:CCRT +AC χ2 = 0.489,
P = 0.484; NACT + CCRT: CCRT + AC χ2 = 0.182,P= 0.670).
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Table 2 Patterns of failure in the 198 patients after
treatment
Patterns of failure IMRT
alone
CCRT NACT + CCRT CCRT + AC
Recurrence
Primary recurrence 3 0 3 0
Nodal recurrence 1 2 0 0
Primary, nodal recurrence 1 1 1 1
Distant metastasis
Bone metastasis 3 9 3 0
Lung metastasis 0 2 6 0
Liver metastasis 2 6 3 0
Mediastinal metastasis 1 0 0 0
Mutiple metastasis 8 6 8 2
Distant metastasis, Primary
and/or nodal recurrence
2 2 3 0
Abbreviation: IMRT alone: intensity-modulated radiotherapy alone; CCRT: concurrent
chemoradiotherapy, NACT + CCRT: neoadjuvant chemotherapy and concurrent
chemoradiotherapy; CCRT + AC: concurrent chemoradiotherapy and
adjuvant chemotherapy.
Table 4 Multivariate analysis for various clinical endpoints
Endpoint Characteristic HR 95.0% CI P
RFS Treatment method 0.667 0.467 0.953 0.026
DMFS
Treatment method 0.694 0.561 0.859 0.001
N stage 2.560 1.304 5.029 0.006
T stage 1.772 1.246 2.522 0.001
PFS
Treatment method 0.674 0.556 0.818 <0.001
T stage 1.645 1.190 2.275 0.003
N stage 2.004 1.039 3.867 0.038
OS Treatment method 0.621 0.497 0.775 <0.001
N stage 2.782 1.372 5.642 0.005
T stage 1.902 1.321 2.740 0.001
Abbreviation: HR: hazard ratio; CI: Confidence interval.
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3 vomiting. Seventeen patients developed grade 3 and 3 pa-
tients developed grade 4 neutropenia. And 9 patients had
grade 3 or 4 thrombocytopenia. The most common severe
acute hematologic toxicities (grade ≥ 3) were leukopeniaTable 3 Univariate analysis for various clinical endpoints
Characteristic N OS(5-year) p DMFS(5-yea
Age(years) 0.448
≤41 100 72.3% 66.8%
>41 98 66.2% 64.4%
Gender 0.451
Male 156 66.5% 65.1%
Female 42 78.1% 66.4%
T stage 0.018
T1-2 71 75.1% 72.1%
T3 95 70.9% 67.2%
T4 32 48.6% 43.4%
N stage 0.145
N2 172 71.0% 67.9%
N3 26 55.7% 50.1%
Histology 0.735
WHO I-II 22 71.3% 67.9%
WHO III 176 68.6% 65.2%
Treatment method <0.001
IMRT alone 33 47.7% 49.2%
Chemoradoitherapy 165 73.1% 68.5%and/or neutropenia n = 20 (30.8%) and thrombocytopenia
n = 9 (5.5%).
Late toxicities were assessed in 152 patients (26 pa-
tients in the IMRT alone group and 126 patients in the
chemoradiotherapy group) with ≥ 2 years follow up. The
most common late toxicities were grade 1 or 2 xerosto-
mia, tympanitis, and subcutaneous fibrosis. No patient




















Table 5 The Frequency of late toxicities for the patients after treatment
Toxicity IMRT alone (n = 26) Chemoraditherapy (n = 126)
Grade 1 no.(%) Grade 2 no.(%) Grade 3 no.(%) Grade 1 no.(%) Grade 2 no.(%) Grade 3 no.(%)
Xerostomia 14(53.8) 1(3.8) 0(0) 64(50.8) 36(28.6) 0(0)
Tympanitis 9(34.6) 7(26.9) 0(0) 50(39.7) 38(30.2) 2(1.6)
Subcutaneous fibrosis 10(38.5) 7(26.9) 0(0) 54(42.8) 39(31.0) 2(1.6)
Trismus 2(7.7) 0(0) 0(0) 7(5.6) 0(0) 0(0)
Temporal lobe injury 1(3.8) 1(3.8) 0(0) 7(5.5) 2(1.6) 0(0)
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Radiotherapy is the principal treatment modality for non-
metastasis NPC. N-stage is a prognostic factor of distant
metastasis of NPC patients, no matter which radiation
technique we used, the advanced N-stage patients had
a high distant metastasis rate [2,9-12] (Table 6).In the
present study, of 198 advanced N-stage NPC patients
treated with IMRT, stage N2 and N3 patients with 5-year
OS, RFS, DMFS, PFS of 71.0%, 88.9%, 67.9%, 61.1%, and
55.%, 91.3%, 50.1%, 50.1%, respectively. Although IMRT
achieved an excellent locoregional control, the DMFS and
OS are still low, and similar to the patients undergoing 2D-
CRT in the past studies [9-11]. Lai et al. [11] compared theTable 6 Summary of the Studies Reporting DMFS and OS
of advanced N-stage NPC patients
Author Year N Technique of RT DMFS(%) OS(%)




Ma, et al [10] 2001 621 2D-CRT 5-year: —
N2:62
N3:51






Wong, et al [2] 2010 175 IMRT 3-year: —
N2:76.6
N3:67.3
Yi, et al [12] 2008 147 IMRT 3-year: 3-year:
N2-3:65.2 N2-3:68.5
Current study 2012 198 IMRT 5-year: 5-year:
N2:68.5 N2:71.0
N3:50.1 N3:55.7results of IMRT with those of 2D-CRT in the treatment of
NPC patients and found that IMRT did not improve dis-
tant control of all N category tumors, the reason might be
the nasopharyngeal carcinoma have a higher probability of
micrometastatic dissemination at the time of initial diagno-
sis, and until effective methods to treat disseminated dis-
ease are developed, the effect of local control on survival
would not be readily discerned. The high distant metastasis
rate may be one reason of the low OS rate. Moreover, in
the present study, OS, RFS, DMFS and PFS rates were sig-
nificantly higher in patients treated with chemoradiother-
apy than those treated with IMRT alone. Although to our
knowledge,there was no randomized phase III study to
confirm the value of chemotherapy on locoregionally ad-
vanced NPC treated with IMRT, according to our results,
chemotherapy still play an important role in the treatment
of advanced N-stage NPC patents.
Intergroup study 0099 [4] demonstrated that CCRT +
AC is superior to radiotherapy alone for locoregionally
advanced NPC patients with respect to PFS and OS.
However, the phase III randomized study in endemic re-
gions did not achieve similar results [13]. Recently, a com-
parison between concurrent chemoradiotherapy followed
by adjuvant chemotherapy and concurrent chemoradio-
therapy was performed in 508 locally advanced NPC pa-
tients enrolled in a phase III trial conducted by Chen et al.
[14]. In this trial, concurrent chemoradiotherapy followed
by adjuvant chemotherapy did not significantly improve
PFS. The meta-analysis by Baujat et al. [5] indicated that
the OS benefit is 6% with the use of chemotherapy, and
the benefit is largely owing to the CCRT. No evidence of
prognostic benefit was observed with adjuvant chemo-
therapy. The other meta-analysis [6] also demonstrated
that CCRT was the most effective treatment modality for
the improvement of survival. However, most patients in
the former studies were treated with 2D-CRT. But IMRT
could increase the dose conformity and irradiate higher
dose to the treatment targets, so the locoregional control
was improved significantly [15,16]. Therefore, the margin
of benefit potentially gained with additional chemotherapy
maybe reduced. Lin et al. [17] have questioned the role
of concurrent chemotherapy in advanced NPC patients
treated with IMRT. In the present study, compared with
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PFS of advanced N-stage patients. The possible reason
is most advanced N-stage patients also with advanced
T-stage. Hara et al. [18] found that although treated
with IMRT, the local failure rate was still more than 10%
in stage T3/4 NPC patients. Larger tumors are related to
adverse radiobiological parameters, including an increased
clonogen number [19,20] and hypoxia[21,22], which are
difficult to overcome with dose escalation alone. In this
case, concurrent chemotherapy could still enhance the ra-
diosensitivity to improve locoregional control. And we
also observed that compared with IMRT alone, there was
only a trend toward a lower distant failure rate with CCRT,
but the correlation did not reach statistical significance
(p = 0.107). CCRT alone is ineffective in reducing dis-
tant metastasis maybe is a reasonable explanation [23].
Moreover, we found even though CCRT +AC group have
higher OS, RFS and PFS than IMRT alone group, the dif-
ferences of survival rates between CCRT +AC and CCRT
group did not reach statistical significance. So maybe the
survival benefit of CCRT +AC is largely owing to the
CCRT. Adjuvant chemotherapy did not improve prognosis
yet. But although the survival rates of CCRT +AC group
did not reach statistical significance when compared with
CCRT or NACT +CCRT group, we observed this group
had the highest survival rates in the three groups. This
phenomenon maybe explained by the small number of pa-
tients treated with CCRT +AC, and the same N2 stage of
all the 11 patients.
The role of neoadjuvant chemotherapy followed by
concurrent chemoradiotherapy or RT is a matter of out-
standing interest. The pool data analysis by Chua et al.
[24] found NACT + RT arm was associated with a sig-
nificant improvement in locoregional relapse-free sur-
vival and disease-specific survival in advanced-stage
NPC, but not in OS. Hui et al. [25] published the re-
sults of a randomized phase II trial in which stage
III-IVb NPC patients were randomly assigned to re-
ceive either NACT + CCRT, or CCRT alone. A positive
impact on survival was observed, since the 3-year over-
all survival for the NACT + CCRT versus the CCRT
arm was 94.1% vs.67.7% (p = 0.012).The present study
demonstrated that the differences of survival rates
between NACT + CCRT and CCRT groups did not
reach statistical significance. So the survival benefit of
CCRT + AC maybe is mainly owing to the CCRT. How-
ever, compared with IMRT alone, NACT + CCRT could
improve DMFS rate significantly, while there was only
a trend with CCRT. Maybe in the condition of such a
high locoregional control by CCRT, NACT + CCRT is
unlikely to improve RFS rate significantly. But because
of more powerful than concurrent chemoradiotherapy,
NACT might be effective in controlling micrometastatic
dissemination.Conclusion
In this study, we have described the long-term outcomes
for patients with advanced N-stage NPC who underwent
IMRT with the SMART boost technique. Compared with
IMRT alone, CCRT could significantly improve OS, RFS,
PFS of advanced N-stage patients, and NACT +CCRT
could significantly improve DMFS. There was no evidence
of survival benefit was observed with adjuvant chemother-
apy in this study. So, according to the results of the present
study, NACT +CCRT might be a reasonable strategy for
advanced N-stage NPC patients. However, our study was
limited by the small sample size, use of retrospective ana-
lysis, and possible selection bias during the matching
process. As a result, relative randomized clinical trial is
still needed in the future. In addition, although an excel-
lent locoregional control was achieved by IMRT, the
DMFS and OS were not improved compared with the ad-
vanced N-stage patients undergoing 2D-CRT. New strat-
egies combining different treatment modalities to reduce
the rate of distant metastasis effectively also need to be de-
veloped in the future.
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